JBL Your CRDMO Partner in Science
JA
EN
  • About Us
    • Vision, Values & Promise
    • Company Overview
    • Leadership Team
    • Our Facilities
    • Contact Us
  • Services
    • Integrated Drug Discovery
      • Target Identification
      • Target Validation
      • HIT Identification
      • HIT to Lead
      • Lead Optimization
      • Candidate Selection
    • Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Analytical Chemistry
      • Computational Chemistry
      • Specialised Chemistry-COE
      • Oligonucleotide Offerings
    • Protein Sciences and Crystallography
      • Custom Protein Production
      • SPR
      • Crystallography
      • SBDD
    • Assay Biology
      • In-Vitro Biology
      • Target Validation
      • Bio-Chemical Assay, D&S
      • Cell Based Assay, D&S
      • Mode of Action Studies
      • Biomarker Evaluation
    • DMPK
      • Physicochemical Properties
      • In-Vitro ADME
      • In-Vivo Pharmacokinetics
      • Drug Interactions
      • Metabolite Identification
      • Bioanalysis
      • Large Molecule Bioanalysis
    • Computational Chemistry (CADD)
      • Virtual Screening
      • LBDD
      • Insilico FBDD
      • Chemoinformatics
    • Pharmacology
      • Oncology Animal Models
      • Inflammation Animal Models
      • Pain and Neuroscience Animal Models
      • Diabetes & Metabolic Disorders Animal Models
    • Toxicology
      • GLP & Non GLP Studies
      • Acute Toxicity
      • Subchronic Toxicity
      • Genetic Toxicity
      • Safety Pharmacology
      • Toxicokinetics
    • CDMO
      • Process R&D Services
      • Analytical Development
      • Process Safety Studies
      • Polystate Capabilities
      • Technology Transfer
      • Early to Late Phase Supplies
      • GLP, Non-GMP and GMP Mfg.
    • Biologics
      • Recombinant Protein Production
      • ADC Capabilities
      • API
        • API Capabilities
    • For more information reach us at: bd@jubilantbiosys.com
  • Target Approaches
    • Kinases
    • Non-Kinase Enzymes
    • GPCRs & Ion Channels
    • Transcription Factors
    • Immune Regulators
    • Target Protein Degradation
    • RNA Small Molecule Drugs
  • Our Commitment
    • EHS
    • Corporate Governance
    • Corporate Social Responsibility
    • Sustainability
    • Quality & IP
    • Policies
  • Resources
    • News
    • Press Releases
    • Events
    • Publications
    • Whitepapers
    • Brochures
    • Webinars
    • Customer Testimonials
    • Annual Return
  • Careers
    • Job Opportunities
    • Job Opportunities in France
    • Returning Indian Talent
    • Recruitment Fraud Advisory
    • Group Ombudsperson

Author: ddAdmin

Jubilant Biosys: A Leading CRO’s Digital Data Transformation

Posted on December 15, 2020March 18, 2025 by ddAdmin
Jubilant Biosys: A Leading CRO’s Digital Data Transformation
Posted in Whitepapers

Soy Protein-Based Hydrogel under Microwave-Induced Grafting of Acrylic Acid and 4‑(4-Hydroxyphenyl)butanoic Acid.

Posted on September 4, 2020March 18, 2025 by ddAdmin
Soy Protein-Based Hydrogel under Microwave-Induced Grafting of Acrylic Acid and 4‑(4-Hydroxyphenyl)butanoic Acid.

Authors: Saloni Mehra, Safiya Nisar, Sonal Chauhan, Virender Singh, and Sunita Rattan 

Posted in Publications

Jubilant Biosys Limited Announces The Merger With Jubilant Chemsys Limited

Posted on July 28, 2020June 20, 2025 by ddAdmin
Jubilant Biosys Limited Announces The Merger With Jubilant Chemsys Limited

Bengaluru, India 28th July, 2020

Jubilant Biosys Limited (“Biosys”), a wholly owned subsidiary of Jubilant Life Sciences Limited, today announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India. The combined entities will now operate as Jubilant Biosys Limited.

Posted in Press Releases

An in vitro model of hepatic steatosis using lipid loaded induced pluripotent stem cell derived hepatocyte like cells

Posted on July 28, 2020March 18, 2025 by ddAdmin
An in vitro model of hepatic steatosis using lipid loaded induced pluripotent stem cell derived hepatocyte like cells

Authors: Hiraganahalli Bhaskar Deepak, Nellikalaya Shreekrishna, Zaheerbasha Sameermahmood, Niranjan Naranapur Anand, Raghotham Hulgi, Juluri Suresh, Sonal Khare, Saravanakumar Dhakshinamoorthy 

Posted in Publications

A CRO that supports drug discovery ideas and passion – Jubilant Biosys

Posted on June 17, 2020March 18, 2025 by ddAdmin
A CRO that supports drug discovery ideas and passion – Jubilant Biosys

BIO Impact Interview June 2020 with Dr Takeshi Yura

Posted in Publications

PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits

Posted on June 16, 2020March 18, 2025 by ddAdmin
PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits

Authors: Feng Yi, Nirvan Rouzbeh, Kasper B. Hansen, Yuelian Xu, Christopher M. Fanger, Earl Gordon, Kathy Paschetto, Frank S. Menniti,∗, Robert A. Volkmann

Posted in Publications

Jubilant Life Sciences grants an exclusive license to Lengo Therapeutics to Discover and Develop Oncology Medicines

Posted on May 13, 2020March 18, 2025 by ddAdmin
Jubilant Life Sciences grants an exclusive license to Lengo Therapeutics to Discover and Develop Oncology Medicines

“Company formation is one of our core activities at Frazier, and Jubilant has been a key part of several of our early-stage companies” Daniel Estes, Ph.D., General Partner on the Frazier Life Sciences team.

Posted in Press Releases

Need an Inspired Chemistry Team to Work on your Business?

Posted on March 18, 2020March 18, 2025 by ddAdmin
Need an Inspired Chemistry Team to Work on your Business?
Posted in Whitepapers

Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors

Posted on March 2, 2020March 18, 2025 by ddAdmin
Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors

Authors: Patrick M. Callahan, Alvin V. Terry Jr., Frederick R. Nelson, Robert A. Volkmann, A.B. Vinod, Mohd Zainuddin, Frank S. Menniti

Posted in Publications

Incurred sample reanalysis of cefuroxime in rabbit ocular tissues – A case study

Posted on January 28, 2020March 18, 2025 by ddAdmin
Incurred sample reanalysis of cefuroxime in rabbit ocular tissues – A case study

Authors: Bhavesh Babulal Gabani, Vinay Kiran, Shuvranshu Praharaj, Nuggehally R. Srinivas, Ramesh Mullangi

Posted in Publications

Posts navigation

Older posts
Newer posts

Get in touch

For Business Queries
bd@jubilantbiosys.com
For Career Related Queries
careers@jubilantbiosys.com

Services

  • Integrated Drug Discovery
  • Chemistry
  • Protein Sciences and Crystallography
  • Assay Biology
  • DMPK
  • Computational Chemistry (CADD)
  • Pharmacology
  • Toxicology
  • CDMO

Our Locations

    R&D Centers
  • Noida, India
  • Greater Noida, India
  • Bengaluru, India
  • Saint Julien, France
Manufacturing Plant
  • Nanjangud, India

Company

  • Facilities
  • Contact
  • Careers
  • News

© 2026 Jubilant Biosys Limited A Jubilant Pharmova Limited Company

  • Policies
  • Jubilant Bhartia Group
  • Sitemap
  • Disclaimer
  • Payment

Request For Information

We appreciate all business enquiries, If you'd like our Business Development team to contact you, please complete this form.

    We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness of campaigns and analyse traffic. If you continue to use this site, we will assume your acceptance.

    PRIVACY POLICY